AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...

Keith Hale has been appointed as Group CEO of Titian Software and Labguru (BioData Inc.), two leading providers of laboratory data management solutions, as part of the goal to accelerate the future of ...

President, Chief Financial Officer. Simon will oversee the overall financial strategy and management of this leading provider of wealth management ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.